Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$5.63 - $8.27 $28,358 - $41,655
-5,037 Reduced 16.83%
24,889 $168,000
Q3 2023

Nov 13, 2023

BUY
$6.71 - $11.83 $113,204 - $199,583
16,871 Added 129.23%
29,926 $200,000
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $145,171 - $289,821
13,055 New
13,055 $149,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.